Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial

The Lancet

Volumn 391, Issue 10115, 2018, Pages 41-50

  Varenne, Olivier ^a,b   Cook, Stéphane ^c   Sideris, Georgios ^d   Kedev, Sasko ^e   Cuisset, Thomas ^f   Carrié, Didier ^g   Hovasse, Thomas ^h   Garot, Philippe ^h   El Mahmoud, Rami ⁱ   Spaulding, Christian ^j   Helft, Gérard ^k   Diaz Fernandez, José F ^l   Brugaletta, Salvatore ^m   Pinar Bermudez, Eduardo ⁿ   Mauri Ferre, Josepa ^o   Commeau, Philippe ^p   Teiger, Emmanuel ^q   Bogaerts, Kris ^r,s   Sabate, Manel ^m   Morice, Marie Claude ^t   Sinnaeve, Peter R ^u   more..

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Fribourg Hospital   (Switzerland)

^d INSERM   (France)

^e SS CYRIL AND METHODIUS UNIVERSITY   (Macedonia)

^f TIMONE HOSPITAL   (France)

^g CHU RANGUEIL   (France)

^h Peupliers Private Hospital   (France)

ⁱ LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^j HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^k PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^l Juan Ramón Jiménez University Hospital   (Spain)

^m HOSPITAL CLÍNIC   (Spain)

ⁿ HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^o HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^p Service de cardiologie   (France)

^q UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^r KU LEUVEN   (Belgium)

^s HASSELT UNIVERSITY   (Belgium)

^t European Cardiovascular Research Center   (France)

^u UNIVERSITY HOSPITALS LEUVEN   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ALL CAUSE MORTALITY; ARTICLE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DUAL ANTIPLATELET THERAPY; FEMALE; GERIATRICS; HEART INFARCTION; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR ADVERSE CARDIAC EVENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; POST HOC ANALYSIS; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SILENT MYOCARDIAL ISCHEMIA; SINGLE BLIND PROCEDURE; STENT COMPLICATION; STENT THROMBOSIS; TARGET LESION REVASCULARIZATION; AGE; DRUG ELUTING STENT; TREATMENT OUTCOME; VERY ELDERLY;

ANTITHROMBOCYTIC AGENT;

AGE FACTORS; AGED; AGED, 80 AND OVER; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 85032994740     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)32713-7     Document Type: Article

References (29)

1. Masoudi, FA, Ponirakis, A, de Lemos, JA, et al. Executive summary: trends in U.S. cardiovascular care: 2016 report from 4 ACC national cardiovascular data registries. J Am Coll Cardiol 69 (2017), 1424–1426.
2. Gerber, Y, Rihal, CS, Sundt, TM 3rd, et al. Coronary revascularization in the community. A population-based study, 1990 to 2004. J Am Coll Cardiol 50 (2007), 1223–1229.
3. Li, L, Geraghty, OC, Mehta, Z, Rothwell, PM, for the Oxford Vascular Study. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet 390 (2017), 490–499.
4. Rich, MW, Chyun, DA, Skolnick, AH, et al. for the American Heart Association Older Populations Committee of the Council on Clinical Cardiology Council on Cardiovascular and Stroke Nursing Council on Cardiovascular Surgery and Anesthesia Stroke Council for the American College of Cardiology, for the American Geriatrics Society. Knowledge gaps in cardiovascular care of the older adult population: a Scientific Statement from the American Heart Association, American College of Cardiology, and American Geriatrics Society. J Am Coll Cardiol 67 (2016), 2419–2440.
5. de Belder, A, de la Torre Hernandez, JM, Lopez-Palop, R, et al., for the XIMA Investigators. A prospective randomized trial of everolimus-eluting stents versus bare-metal stents in octogenarians: the XIMA Trial (Xience or Vision Stents for the Management of Angina in the Elderly). J Am Coll Cardiol 63 (2014), 1371–1375.
6. Urban, P, Meredith, IT, Abizaid, A, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med 373 (2015), 2038–2047.
7. Morice, MC, Talwar, S, Gaemperli, O, et al. Drug-coated versus bare-metal stents for elderly patients: a predefined sub-study of the LEADERS FREE trial. Int J Cardiol 243 (2017), 110–115.
8. Palmerini, T, Benedetto, U, Biondi-Zoccai, G, et al. Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol 65 (2015), 2496–2507.
9. Byrne, RA, Serruys, PW, Baumbach, A, et al. Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. Eur Heart J 36 (2015), 2608–2620.
10. Valgimigli, M, Patialiakas, A, Thury, A, et al., for the ZEUS investigators. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol 65 (2015), 805–815.
11. Bønaa, KH, Mannsverk, J, Wiseth, R, et al., for the NORSTENT Investigators. Drug-eluting or bare-metal stents for coronary artery disease. N Engl J Med 375 (2016), 1242–1252.
12. Gerber, RT, Arri, SS, Mohamed, OM, et al. Age is not a bar to PCI: insights from the long-term outcomes from off-site PCI in a real-world setting. J Interv Cardiol 30 (2017), 347–355.
13. Windecker, S, Kolh, P, Alfonso, F, et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35 (2014), 2541–2619.
14. Levine, GN, Bates, ER, Bittl, JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol 68 (2016), 1082–1115.
15. Roffi, M, Patrono, C, Collet, JP, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 37 (2016), 267–315.
16. Varenne, O, Cuisset, T, Chaïb, A, et al. The SYNERGY II everolimus eluting stent in patients older than 75 years undergoing coronary revascularisation associated with a short dual antiplatelet therapy (SENIOR) trial: rationale and design of a large-scale randomised multicentre study. EuroIntervention 12 (2017), 1614–1622.
17. Thygesen, K, Alpert, JS, Jaffe, AS, et al. Third universal definition of myocardial infarction. Eur Heart J 33 (2012), 2551–2567.
18. Mehran, R, Rao, SV, Bhatt, DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123 (2011), 2736–2747.
19. Cutlip, DE, Windecker, S, Mehran, R, et al. Clinical endpoints in coronary stent trials: a case for standardized definitions. Circulation 115 (2007), 2344–2351.
20. Alexander, KP, Newby, LK, Cannon, CP, et al. Acute coronary care in the elderly, part I: non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation 115 (2007), 2549–2569.
21. Yeh, RW, Secemsky, EA, Kereiakes, DJ, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA 315 (2016), 1735–1749.
22. Baber, U, Mehran, R, Giustino, G, et al. Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS. J Am Coll Cardiol 67 (2016), 2224–2234.
23. Forman, DE, Cox, DA, Ellis, SG, et al. Long-term paclitaxel-eluting stent outcomes in elderly patients. Circ Cardiovasc Interv 2 (2009), 178–187.
24. Palmerini, T, Della Riva, D, Benedetto, U, et al. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients. Eur Heart J 38 (2017), 1034–1043.
25. Colmenarez, H, Fernández, C, Escaned, J, Impact of technological developments in drug-eluting stents on patient-focused outcomes: a pooled direct and indirect comparison of randomised trials comparing first and second-generation drug-eluting stents. EuroIntervention 10 (2014), 942–952.
26. D'Ascenzo, F, Iannaccone, M, Saint-Hilary, G, et al. Impact of design of coronary stents and length of dual antiplatelet therapies on ischaemic and bleeding events: a network meta-analysis of 64 randomized controlled trials and 102 735 patients. Eur Heart J, 2017 published online Aug 11. DOI:10.1093/eurheartj/ehx437.
27. Valgimigli, M, Bueno, H, Byrne, RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J, 2017 published online Aug 26. DOI:10.1093/eurheartj/ehx419.
28. Mauri, L, Kereiakes, DJ, Yeh, RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371 (2014), 2155–2166.
29. Piccolo, R, Gargiulo, G, Franzone, A, et al. Use of the dual-antiplatelet therapy score to guide treatment duration after percutaneous coronary intervention. Ann Intern Med 167 (2017), 17–25.